2019 年年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2019 年年度报告 1 / 221 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 大华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张海明、主管会计工作负责人张海明及会计机构负责人（会计主管人员）黄俊芹 声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 根据大华会计师事务所（特殊普通合伙）对公司2019年度财务状况的审计，公司2019年度合 并后实现归属于母公司所有者的净利润12,151,225.23元，母公司可供股东分配利润为 273,341,824.32元。 综合考虑公司所处发展阶段和未来成长需求，2019年度利润分配预案为：拟以实施权益分派 股权登记日登记的总股本为基数分配利润,向全体股东每10股派发现金红利0.06元（含税） ...

2020 年第一季度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2020 年第一季度报告 2020 年 4 月 1 / 21 2020 年第一季度报告 重要提示 . 一、 二、 公司基本情况 . 11Í 重要事项 . 四、 附录 . 目录 2 / 21 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张海明、主管会计工作负责人张海明及会计机构负责人（会计主管人员）黄俊芹 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|------------------|----------------------|------ ...

2019 年第三季度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2019 年第三季度报告 1 / 28 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 28 2019 年第三季度报告 单位：元 币种：人民币 3 / 28 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张海明、主管会计工作负责人高建及会计机构负责人（会计主管人员）黄俊芹保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------ ...

2019 年半年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2019 年半年度报告 1 / 152 2019 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张海明、主管会计工作负责人高建及会计机构负责人（会计主管人员）黄俊芹声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质性承诺 ，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 2019 年由于受到"非洲猪瘟"疫情扩散的影响，生猪存栏和能繁母猪存栏相比去年同期都大 幅下滑，由于公司主营业务中猪用疫苗的销售占比达 ...

2018 年年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 陈连勇 工作原因 张海明 三、 大华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张海明、主管会计工作负责人高建及会计机构负责人（会计主管人员）黄俊芹声明： 保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 根据大华会计师事务所（特殊普通合伙）对公司2018年度财务状况的审计，公司2018年度合并 后实现归属于母公司所有者的净利润21,298,223.87元，母公司可供股东分配利润为 257,267,526.69元。 综合考虑公司所处发展阶段和未来成长需求，2018年度利润分配预案为：以2018年末总股本 644,000,000股为基数，向全 ...

Financial Performance - Operating revenue for the first quarter reached CNY 80,956,247.28, a 31.04% increase year-on-year[6] - Net profit attributable to shareholders decreased by 68.52% to CNY 6,489,569.29 compared to the same period last year[6] - Total operating revenue for Q1 2019 was CNY 80,956,247.28, an increase of 30.96% compared to CNY 61,780,112.64 in Q1 2018[29] - Net profit for Q1 2019 was CNY 2,138,649.36, down 87.84% from CNY 17,526,158.26 in Q1 2018[31] - The profit attributable to shareholders of the parent company decreased to CNY 6,489,569.29, a decline of 68.42% compared to CNY 20,614,166.42 in the previous year[31] - Total profit for Q1 2019 was CNY 1,005,453.99, a decrease of 94.86% from CNY 19,534,897.82 in Q1 2018[29] - The total comprehensive income for Q1 2019 was CNY 2,138,649.36, a decrease of 87.84% from CNY 17,526,158.26 in Q1 2018[31] Cash Flow - Net cash flow from operating activities surged by 210.67% to CNY 3,741,411.96 compared to the previous year[6] - The net cash flow from operating activities for Q1 2019 was ¥3,741,411.96, compared to ¥1,204,316.89 in Q1 2018, indicating an increase of about 210.5%[39] - The cash inflow from sales and services reached ¥66,359,239.06, a significant increase from ¥40,681,805.60 in Q1 2018, representing a growth of approximately 63.2%[38] - The total cash outflow from operating activities in Q1 2019 was ¥83,100,591.39, compared to ¥41,535,654.75 in Q1 2018, an increase of about 99.8%[39] - The cash flow from financing activities in Q1 2019 was ¥6,401,875.00, down from ¥15,468,213.70 in Q1 2018, a decrease of approximately 58.7%[40] Assets and Liabilities - Total assets increased by 0.19% to CNY 1,751,841,491.28 compared to the end of the previous year[6] - The company reported a total current asset of approximately RMB 783.81 million as of March 31, 2019, compared to RMB 787.47 million at the end of 2018[23] - Total liabilities stood at CNY 723,942,927.27, slightly up from CNY 722,814,499.85, representing a marginal increase of 0.16%[25] - Current liabilities decreased to CNY 656,258,689.49 from CNY 657,313,262.07, indicating a reduction of about 0.16%[24] - Shareholders' equity totaled CNY 1,027,898,564.01, an increase from CNY 1,025,759,914.65, showing a growth of approximately 0.21%[25] Research and Development - Research and development expenses rose by 135.27% to CNY 8,714,031.34 due to an increase in the scope of consolidation[12] - Research and development expenses increased significantly to CNY 8,714,031.34, a 134.06% rise from CNY 3,703,777.96 in Q1 2018[29] - Shanghai Jiemen Biotechnology Co., a wholly-owned subsidiary, achieved continuous growth in all financial indicators and exceeded performance targets, increasing R&D spending on future star products[15] - The company plans to continue focusing on self-research and production to provide cost-effective in vitro diagnostic products and services[15] Shareholder Information - The number of shareholders reached 18,554, with the largest shareholder holding 50.90% of the shares[11] Investment Income - Investment income decreased by 41.84% to CNY 5,334,469.61, primarily due to reduced financial investment returns[12] - The company experienced a net investment income of CNY 5,334,469.61, down 41.73% from CNY 9,172,705.58 in Q1 2018[29] Inventory and Accounts Receivable - The company reported a significant increase of 38.76% in accounts receivable, totaling CNY 83,331,819.37, attributed to increased government procurement sales[12] - Accounts receivable increased from RMB 60.05 million at the end of 2018 to RMB 83.33 million as of March 31, 2019[23] - Inventory decreased from RMB 128.76 million at the end of 2018 to RMB 115.90 million as of March 31, 2019[23] - Inventory decreased to CNY 52,042,408.31 from CNY 56,733,250.79, indicating a decline of about 8.25%[27] Regulatory and Compliance - The company executed a new financial instrument standard starting January 1, 2019, affecting the financial statement format[48] - The financial statement format has been revised according to the Ministry of Finance's notification[52] - There are no adjustments for the new financial instrument and leasing standards applicable for prior comparative data[53] - The audit report is not applicable for this period[53] - The company has not reported any treasury stock[52]

2018 年年度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 陈连勇 工作原因 张海明 三、 大华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张海明、主管会计工作负责人高建及会计机构负责人（会计主管人员）黄俊芹声明： 保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 根据大华会计师事务所（特殊普通合伙）对公司2018年度财务状况的审计，公司2018年度合并 后实现归属于母公司所有者的净利润21,298,223.87元，母公司可供股东分配利润为 257,267,526.69元。 综合考虑公司所处发展阶段和未来成长需求，2018年度利润分配预案为：以2018年末总股本 644,000,000股为基数，向全 ...

上海海利生物技术股份有限公司 2018 年第三季度报告 公司代码：603718 公司简称：海利生物 上海海利生物技术股份有限公司 2018 年第三季度报告 2018 年 10 月 1 / 23 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 11 | 上海海利生物技术股份有限公司 2018 年第三季度报告 2.1 主要财务数据 | | | | | 本报告期末比 | | | | --- | --- | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | | 上年度末增减 | | | | | | | | (%) | | | | 总资产 | 1,778,645,325.16 | 1,601,718,423.82 | | 11.05 | | | | 归属于上市公司股东的净资产 | 1,080,630,833.12 | 1,069,559,314.91 | | 1.04 | | | | | 年初至报告期末 | 上年初至上年报告期末 | | 比上年同期增 | | | | | （ ...

Financial Performance - The company's basic earnings per share for the first half of 2018 was CNY 0.04977, a decrease of 40.46% compared to CNY 0.08359 in the same period last year[18]. - The net profit attributable to shareholders decreased by 40.46%, primarily due to a significant drop in domestic pig prices and reduced demand for vaccine products, leading to a 26.42% decline in operating revenue[18]. - The weighted average return on net assets was 2.95%, down 2.39 percentage points from 5.34% in the previous year[18]. - The net cash flow from operating activities decreased by 284.95%, attributed to the decline in operating revenue and an increase in employee compensation payments[19]. - The company's operating revenue for the first half of the year was CNY 107,970,637.10, a decrease of 26.42% compared to CNY 146,744,445.23 in the same period last year[21]. - The net profit attributable to shareholders for the same period was CNY 32,051,182.67, down 40.46% from CNY 53,834,706.01 year-on-year[21]. - The net cash flow from operating activities was negative CNY 25,008,969.01, a decline of 284.95% compared to CNY 13,521,986.23 in the previous year[21]. - The company's consolidated sales revenue for the first half of 2018 was 107.97 million, a decrease of 26.42% compared to the same period in 2017[35]. - The net profit attributable to the parent company for the first half of 2018 was 32.05 million, down 40.46% year-on-year[35]. Operating Costs and Expenses - The company's operating costs and financial expenses increased by 21.96% and 63.86%, respectively, compared to the same period last year[18]. - Operating costs increased by 21.96% to ¥34,898,487.57, primarily due to low gross margins from newly launched products[44][45]. - Sales expenses decreased by 27.03% to ¥27,057,813.35, attributed to a reduction in marketing personnel and lower promotional costs[44][45]. Research and Development - The company has established a strong R&D capability and is committed to developing vaccines for livestock, particularly focusing on swine vaccines[23]. - The company plans to enhance its R&D efforts, particularly in response to the ongoing African swine fever outbreak, which is expected to impact the industry significantly[27]. - The company is constructing a new 1200 square meter P2 level laboratory to enhance its new drug research and development capabilities[29]. - The company has multiple vaccine products in various stages of development, including 4 in the new veterinary drug registration phase and 3 in clinical trial phase[31]. - The company has successfully developed large-scale suspension culture technology for various cell lines, which supports the production of vaccines[32]. - The company has established a comprehensive quality control system to ensure the safety and effectiveness of its vaccine products[33]. - The company is adjusting its R&D incentive system and compensation structure to better motivate employees and enhance innovation[29]. Market and Sales Strategy - The sales model includes a combination of distributor sales and direct sales to large customers, covering over 13,000 large-scale farms across the country[24]. - The company has a government procurement component in its sales, although this has been declining due to changes in mandatory vaccination policies since 2017[25]. - The company aims to improve product quality and vaccination effectiveness in line with stricter food safety regulations and increasing demands from the livestock industry[27]. - The company organized 28 customer visit activities in the first half of 2018 to promote its products and enhance sales[36]. - The company has implemented a marketing strategy focused on self-marketing and government procurement, enhancing brand influence through nationwide technical seminars and forums[33]. Financial Position and Assets - The company's total assets increased by 15.39% to CNY 1,848,212,814.32 from CNY 1,601,718,423.82 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 3.00% to CNY 1,101,610,497.58 from CNY 1,069,559,314.91 at the end of the previous year[21]. - Total assets increased to 1,848,000,000.00 CNY, a growth of 44.12% compared to the previous period[47]. - Accounts receivable rose by 230.27% to 59,040,038.92 CNY, primarily due to increased government procurement[47]. - Inventory increased by 44.12% to 143,599,582.62 CNY, attributed to stockpiling and expanded consolidation scope[47]. Shareholder and Equity Information - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[5]. - The company has committed to implementing a stock price stabilization plan if the stock price falls below the net asset value per share for 20 consecutive trading days[64]. - The company will compensate investors for losses incurred due to false statements or omissions in the prospectus, with the compensation amount determined through negotiation or regulatory authority[64]. - The company has pledged to strictly adhere to all public commitments made during the IPO process and will accept social supervision[66]. - The company will not increase salaries or allowances for directors and senior management until all negative impacts from unfulfilled commitments are eliminated[66]. - The company has a long-term commitment to stabilize its stock price and will take measures such as share buybacks and management stock purchases[64]. Environmental Compliance - The company reported that Yangling Jinhai is a key wastewater discharge unit, with no environmental pollution incidents or administrative penalties during the reporting period[88]. - The company’s wastewater discharge met the standards set by the relevant environmental regulations, with total discharge of 305 tons and compliance with the specified limits[89]. - The company’s nitrogen oxide emissions from high stacks were reported at 80 mg/m³, which is within the regulatory limits[91]. - The company has implemented a comprehensive environmental monitoring system, with real-time data transmission to the environmental protection department, ensuring compliance with wastewater discharge standards[94]. Acquisitions and Investments - The company completed the full acquisition of Jiemen Bio, contributing to the growth of its "human health" business segment[43]. - The company invested 298,000,000 CNY to acquire 100% of Jiemen Biological, enhancing its presence in the human health sector[50]. - A joint venture with WuXi Biologics was established with an investment of 150,000,000 CNY, holding a 30% stake in Shanghai WuXi Haide Biotechnology Co., Ltd.[50]. - The company completed the acquisition of Jiemen Biotechnology, with the original shareholders fulfilling their commitment to purchase company stock[82]. Risks and Challenges - The company faced significant challenges due to the "pig cycle," leading to a reduction in vaccine demand and impacting revenue[35]. - The company anticipates a recovery in government procurement income, having won bids in 12 provinces for foot-and-mouth disease vaccines in 2018[57]. - The company faces risks from changes in government procurement policies, which have led to a decrease in government procurement income compared to 2017[56]. - The company is exposed to performance volatility due to fluctuations in the livestock industry and potential animal disease outbreaks, which could impact vaccine sales[58].

Financial Performance - The net profit attributable to the parent company for 2017 was RMB 113,739,532.17, with distributable profits for shareholders amounting to RMB 250,653,195.03[2] - Basic earnings per share increased by 38.46% to CNY 0.18 compared to CNY 0.13 in the previous year[20] - Operating revenue decreased by 11.56% to CNY 303,650,205.36 from CNY 343,338,733.45 in the previous year, primarily due to a significant drop in government procurement revenue[20] - Net profit attributable to shareholders increased by 32.97% to CNY 113,739,532.17 from CNY 85,536,349.91 in the previous year[20] - Net cash flow from operating activities decreased by 67.78% to CNY 34,920,783.42 from CNY 108,388,167.48 in the previous year[21] - The company experienced a decline in net profit after deducting non-recurring gains and losses by 3.59% to CNY 79,897,459.14 from CNY 82,874,662.24 in the previous year[20] - The total profit for the reporting period was CNY 107.12 million, an increase of 39.31% year-on-year, primarily due to the production commencement of a subsidiary and significant investment income[53] - In 2017, the company achieved a sales revenue of CNY 304 million, a decrease of 11.56% compared to the previous year, while net profit increased by 27% to CNY 132.94 million[47] Dividends and Shareholder Returns - A cash dividend of RMB 0.55 per 10 shares (including tax) is proposed, based on a total share capital of 644,000,000 shares as of the end of 2017[2] - In 2017, the company distributed cash dividends totaling RMB 35,420,000, representing 31.14% of the net profit attributable to ordinary shareholders[119] - The cash dividend per 10 shares was RMB 0.55 in 2017, compared to RMB 0.40 in 2016 and RMB 1.00 in 2015[119] Audit and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[5] - The company is committed to ensuring the accuracy and completeness of the annual report, with all board members present at the meeting[5] - There are no non-operating fund occupations by controlling shareholders or related parties reported[4] - The company has not reported any significant accounting errors or changes in accounting policies during the reporting period[132] - The company has not experienced any asset or project profitability forecast issues during the reporting period[132] - The company has not reported any occupied funds or collection progress issues during the reporting period[132] - The company has not received any non-standard audit opinions from its accounting firm[133] Research and Development - The company is a key high-tech enterprise and has a strong R&D capability in the veterinary biological products industry, focusing on vaccine development[28] - The company plans to continue increasing R&D investment and improving product quality to maintain market competitiveness and sustainable development[37] - Research and development expenses increased by 50.35% to CNY 37.78 million, reflecting the company's commitment to enhancing product quality and innovation[55] - The company has established multiple gene engineering technology platforms, including yeast expression and insect cell-baculovirus expression, to support vaccine R&D and production[40] - The company has a strong pipeline of new vaccine products, including the world's first avian DNA vaccine for H5 avian influenza, which offers advantages such as easy storage and transportation[41] - The company is focusing on the development of safe and efficient veterinary vaccines, with a dedicated R&D center led by Dr. Liu Hanping, who has extensive experience in vaccine development[81] - The company aims to provide strong support for the healthy development of the livestock industry in China through its R&D initiatives[81] - The cumulative R&D investment for the main projects is being tracked, with ongoing progress reported regularly[86] Market and Sales Strategy - The company has established a comprehensive dealer management system to enhance sales and ensure brand integrity[29] - Future government procurement remains a significant sales channel, despite the recent decline in revenue from government contracts[30] - The company’s revenue exhibits seasonal characteristics, with higher sales typically occurring in the autumn and winter months due to increased demand for disease prevention[35] - The company’s marketing strategy focuses on self-operated sales and government procurement, with an emphasis on refining channel management and enhancing partner confidence[44] - The company is actively pursuing collaborations with key research institutions in the domestic vaccine field to enhance its R&D capabilities[40] - The company plans to enhance product quality and strengthen technical services to stand out in an increasingly competitive market[107] Risk Management - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting investment risks[3] - The report details various risks faced during production and operations, along with corresponding countermeasures[6] - The company faces risks from policy changes, including the cancellation of mandatory immunization policies for certain diseases[112] Corporate Governance - The company has committed to a stock price stabilization plan if the stock price falls below the latest net asset value per share for 20 consecutive trading days[120] - The company has a long-term commitment to compensate investors for losses due to false statements in the prospectus[121] - The company has established a lock-up period of 36 months for shares held by major shareholders post-IPO, with restrictions on transfer or repurchase during this period[121] - The company has committed to maintaining transparency and accepting social supervision regarding its public commitments made during the IPO process[125] Environmental and Social Responsibility - The company has strengthened its environmental management system, achieving ISO 14001 certification and continuously promoting compliance with environmental regulations[166] - The company actively engaged in social responsibility initiatives, including donations to educational foundations and organizing blood donation activities[163] - The wastewater treatment facility at the subsidiary Yangling Jinhai has a daily processing capacity of 500 m³, utilizing advanced treatment technologies[164] Shareholder Structure - The total number of common shareholders at the end of the reporting period was 18,245, down from 18,942 at the end of the previous month[173] - Shanghai Haoyuan Technology Development Co., Ltd. holds 50.8996% of the shares, totaling 327,793,585 shares, with 100,000,000 shares pledged[174] - The top ten shareholders include Taiping Asset Management with 25,099,974 shares (3.8975%) and Shengke Zhiliang with 21,171,500 shares (3.2875%)[174] Future Outlook - The company provided guidance for Q4 2023, expecting revenue to be between $160 million and $170 million, representing a growth of 10% to 13%[192] - New product launches are anticipated to contribute an additional $30 million in revenue over the next fiscal year[192] - The company is exploring potential acquisitions to bolster its product portfolio, with a budget of $20 million allocated for this purpose[192] - The company plans to enhance its vaccine quality and process technology, focusing on new animal disease vaccines and multivalent vaccines in 2018[91]